Neurotensin in diabetes and obesity

F. J. Service, J. M. Jay, R. A. Rizza, P. C. O'Brien, V. L.W. Go

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Basal and postprandial concentrations of immunoreactive neurotensin were measured in insulin dependent diabetic patients and lean and obese noninsulin dependent diabetic patients when partially withdrawn from subcutaneous (s.c.) insulin treatment and again when near normoglycemia had been achieved from insulin infusion by an artificial endocrine pancreas (AEP). Neither basal nor postprandial neurotensin differed among the 3 groups of diabetic patients during s.c. insulin treatment nor from weight matched nondiabetic subjects. In addition, AEP resulted in no significant change in postprandial neurotensin responses. No differences in neurotensin levels were observed between lean and obese nondiabetic subjects. In contrast to observations in experimental diabetes, these observations do not support the presence of an abnormality of neurotensin in human diabetes.

Original languageEnglish (US)
Pages (from-to)85-92
Number of pages8
JournalRegulatory Peptides
Volume14
Issue number1
DOIs
StatePublished - Mar 1986

    Fingerprint

Keywords

  • artificial pancreas
  • diabetes
  • neurotensin
  • obesity

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Endocrinology
  • Clinical Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Service, F. J., Jay, J. M., Rizza, R. A., O'Brien, P. C., & Go, V. L. W. (1986). Neurotensin in diabetes and obesity. Regulatory Peptides, 14(1), 85-92. https://doi.org/10.1016/0167-0115(86)90207-7